Guest Post by William G. Nelson, MD, PhD
Editor-in-Chief, Cancer Today
Do cancer cells have Achilles’ heels? The answer may lie in a concept called synthetic lethality that originated in studies of fruit flies. When fruit flies carry certain defective genes, they appear more or less normal, but when the flies carry a specific combination of these defective genes, they are not viable. The interaction of these combinations of gene defects is called synthetic lethality.
Recently, insights about synthetic lethality have been applied to cancer treatments. The hope is that pairs of synthetic lethal genes can be discovered in which one of a pair contains a cancer gene defect and the partner is a non-defective gene. Because a cancer cell with a defective gene depends on the non-defective gene partner for survival, inhibiting the non-defective gene partner with a drug would kill the cancer cell with few side effects expected on normal cells or tissues.
Alan Ashworth, a British cancer researcher, and his colleagues exploited synthetic lethality to build better treatments for cancers arising from defective BRCA genes; these defective genes are seen commonly in breast, ovarian, and prostate cancers. They discovered that drugs disrupting, or inhibiting, the function of poly (ADP-ribose) polymerases, or PARPs, selectively killed cancer cells with BRCA gene defects. In other words, the BRCA and PARP genes are synthetic lethal pairs. The researchers pursued clinical trials using PARP inhibitors to treat patients with cancers containing defective BRCA genes. The PARP inhibitor Lynparza (olaparib) was approved by the U.S. Food and Drug Administration (FDA) in 2014 to treat patients with advanced ovarian cancer that has BRCA defects. Additional FDA approvals of PARP inhibitors for breast and prostate cancers with BRCA defects have followed. PARP inhibitors may also form synthetic lethal pairs with other defective cancer genes.
High-tech functional genomics screens that analyze the functions and interactions of genes have discovered and cataloged synthetic lethal gene pairs in which one of the gene partners is a defective cancer gene. These efforts offer a promising avenue to new cancer treatments. This treatment model can target vulnerabilities in cancer genes where the defect is loss of function, like BRCA genes, and in cancer genes where the defect may create a gain of function, like overexpression of proteins in MYC and RAS genes.
The concept of synthetic lethality has yielded new approved drugs to treat cancers with BRCA gene defects and is poised to deliver new treatments for other cancers with other defective genes. Hopefully, all cancer cells possess vulnerabilities attributable to acquired gene defects so that, like Achilles’ heel, cancers can be treated with drugs developed to exploit these weaknesses.
William G. Nelson, MD, PhD, is the editor-in-chief of Cancer Today, the quarterly magazine for cancer patients, survivors, and caregivers published by the American Association for Cancer Research. Nelson is the Marion I. Knott professor of oncology and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. You can read his complete column in the summer 2018 issue of Cancer Today.
You may also like: